Cargando…

Reduced glucocerebrosidase activity in monocytes from patients with Parkinson’s disease

Missense mutations in glucocerebrosidase (GBA1) that impair the activity of the encoded lysosomal lipid metabolism enzyme (GCase) are linked to an increased risk of Parkinson’s disease. However, reduced GCase activity is also found in brain tissue from Parkinson’s disease patients without GBA1 mutat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Atashrazm, Farzaneh, Hammond, Deborah, Perera, Gayathri, Dobson-Stone, Carol, Mueller, Nicole, Pickford, Russell, Kim, Woojin Scott, Kwok, John B., Lewis, Simon J. G., Halliday, Glenda M., Dzamko, Nicolas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6193988/ https://www.ncbi.nlm.nih.gov/pubmed/30337601 http://dx.doi.org/10.1038/s41598-018-33921-x

Ejemplares similares

Glucocerebrosidase Activity is Reduced in Cryopreserved Parkinson’s Disease Patient Monocytes and Inversely Correlates with Motor Severity
por: Hughes, Laura P., et al.
Publicado: (2021)

LRRK2 inhibitors and their potential in the treatment of Parkinson’s disease: current perspectives
por: Atashrazm, Farzaneh, et al.
Publicado: (2016)

Lipid pathway dysfunction is prevalent in patients with Parkinson’s disease
por: Galper, Jasmin, et al.
Publicado: (2022)

Comparison of Different Platform Immunoassays for the Measurement of Plasma Alpha-Synuclein in Parkinson’s Disease Patients
por: Youssef, Priscilla, et al.
Publicado: (2021)

Cytokines and Gaucher Biomarkers in Glucocerebrosidase Carriers with and Without Parkinson Disease
por: Galper, Jasmin, et al.
Publicado: (2021)

WHOPPA Enables Parallel Assessment of Leucine-Rich Repeat Kinase 2 and Glucocerebrosidase Enzymatic Activity in Parkinson’s Disease Monocytes
por: Wallings, Rebecca L., et al.
Publicado: (2022)

Effect of LRRK2 protein and activity on stimulated cytokines in human monocytes and macrophages
por: Ahmadi Rastegar, Diba, et al.
Publicado: (2022)

Role of the Long Non-Coding RNA MAPT-AS1 in Regulation of Microtubule Associated Protein Tau (MAPT) Expression in Parkinson's Disease
por: Coupland, Kirsten G., et al.
Publicado: (2016)

Toll-like receptor 2 is increased in neurons in Parkinson’s disease brain and may contribute to alpha-synuclein pathology
por: Dzamko, Nicolas, et al.
Publicado: (2016)

Nigrostriatal pathology with reduced astrocytes in LRRK2 S910/S935 phosphorylation deficient knockin mice
por: Zhao, Ye, et al.
Publicado: (2018)

Evaluation of plasma levels of NFL, GFAP, UCHL1 and tau as Parkinson's disease biomarkers using multiplexed single molecule counting
por: Youssef, Priscilla, et al.
Publicado: (2023)

Sex-specific lipid dysregulation in the Abca7 knockout mouse brain
por: Fu, YuHong, et al.
Publicado: (2022)

A small molecule toll-like receptor antagonist rescues α-synuclein fibril pathology
por: Chedid, Jessica, et al.
Publicado: (2022)

Increased unsaturated lipids underlie lipid peroxidation in synucleinopathy brain
por: Fu, YuHong, et al.
Publicado: (2022)

Parkinsonism Associated with Glucocerebrosidase Mutation
por: Sunwoo, Mun-Kyung, et al.
Publicado: (2011)

Glucocerebrosidase mutations in primary parkinsonism
por: Asselta, Rosanna, et al.
Publicado: (2014)

Glucocerebrosidase mutations and Parkinson disease
por: Vieira, Sophia R. L., et al.
Publicado: (2022)

Evaluation of Strategies for Measuring Lysosomal Glucocerebrosidase Activity
por: Ysselstein, Daniel, et al.
Publicado: (2021)

Parkinson’s disease-implicated kinases in the brain; insights into disease pathogenesis
por: Dzamko, Nicolas, et al.
Publicado: (2014)

Parkinson’s progression prediction using machine learning and serum cytokines
por: Ahmadi Rastegar, Diba, et al.
Publicado: (2019)

Glucocerebrosidase and its relevance to Parkinson disease
por: Do, Jenny, et al.
Publicado: (2019)

Parkinsonisms and Glucocerebrosidase Deficiency: A Comprehensive Review for Molecular and Cellular Mechanism of Glucocerebrosidase Deficiency
por: Gatto, Emilia M., et al.
Publicado: (2019)

Association Between Glucocerebrosidase Mutations and Parkinson's Disease in Ireland
por: Olszewska, Diana A., et al.
Publicado: (2020)

Glucocerebrosidase Involvement in Parkinson Disease and Other Synucleinopathies
por: Almeida, Maria do Rosário
Publicado: (2012)

Progressive decline of glucocerebrosidase in aging and Parkinson's disease
por: Rocha, Emily M, et al.
Publicado: (2015)

The relationship between glucocerebrosidase mutations and Parkinson disease
por: Migdalska‐Richards, Anna, et al.
Publicado: (2016)

Longitudinal Measurements of Glucocerebrosidase activity in Parkinson’s patients
por: Alcalay, Roy N., et al.
Publicado: (2020)

Distinct TDP-43 inclusion morphologies in frontotemporal lobar degeneration with and without amyotrophic lateral sclerosis
por: Tan, Rachel H., et al.
Publicado: (2017)

SCARB2 variants and glucocerebrosidase activity in Parkinson’s disease
por: Alcalay, Roy N, et al.
Publicado: (2016)

Glucocerebrosidase Deficiency in Substantia Nigra of Parkinson Disease Brains
por: Gegg, Matthew E, et al.
Publicado: (2012)

Gait asymmetry in glucocerebrosidase mutation carriers with Parkinson’s disease
por: Gera, Anjali, et al.
Publicado: (2020)

Neuroimaging in Glucocerebrosidase‐Associated Parkinsonism: A Systematic Review
por: Filippi, Massimo, et al.
Publicado: (2022)

Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or Severity
por: Omer, Nurit, et al.
Publicado: (2021)

Biochemical consequences of glucocerebrosidase 1 mutations in Parkinson’s disease
por: Yoon, Jeong Hyun, et al.
Publicado: (2023)

LRRK2 and Lipid Pathways: Implications for Parkinson’s Disease
por: Galper, Jasmin, et al.
Publicado: (2022)

Did α-Synuclein and Glucocerebrosidase Coevolve? Implications for Parkinson’s Disease
por: Gruschus, James M.
Publicado: (2015)

Strong association between glucocerebrosidase mutations and Parkinson's disease in Sweden
por: Ran, Caroline, et al.
Publicado: (2016)

Glucocerebrosidase Defects as a Major Risk Factor for Parkinson’s Disease
por: Avenali, Micol, et al.
Publicado: (2020)

Live cell in situ lysosomal GCase activity correlates to alpha-synuclein levels in human differentiated neurons with LRRK2 and GBA1 mutations
por: Labrador-Garrido, Adahir, et al.
Publicado: (2023)

Inhibitor treatment of peripheral mononuclear cells from Parkinson’s disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker
por: Perera, G., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_f3pjeddsgreuc52b49pepq60ik